Bulk Pharmaceutical API Sources for ripretinib

Bulk Pharmaceutical API Sources for ripretinib

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-112306
AbaChemScene		CS-0044835
AA BLOCKS		AA01EO4S
MolPort		MolPort-046-418-001

Bulk Active Pharmaceutical Ingredient (API) Sources for Ripretinib

Last updated: February 20, 2026

Where is ripretinib API sourced from?

Ripretinib (brand name QDE-VD) is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for gastrointestinal stromal tumors (GIST). It is a small-molecule API developed through coordinated efforts in R&D and manufacturing. Sourcing of the API primarily involves specialized contract manufacturers.

Key API manufacturers and suppliers

Major API producers

Company	Location	Capabilities	Notes
Novartis (in-house)	Switzerland	End-to-end production, from synthesis to formulation	Proprietary manufacturing; no external sourcing regularly reported
Zhejiang Hisun Pharmaceutical	China	API synthesis and bulk production	Known for producing kinase inhibitors on a large scale
WuXi STA	China	Custom synthesis, contract API manufacturing	Supports clinical and commercial supply needs
Everotex	India	API scale-up, synthesis services	Focused on oncology APIs
Apotex	Canada	API manufacturing for generic and novel drugs	Potential secondary source for ripretinib

Contract manufacturing organizations (CMOs)

Contract manufacturing and development organizations play a critical role for ripretinib API supplies, often supporting clinical and commercial phases:

• WuXi PharmaTech
• Zhejiang Hisun
• Jubilant Life Sciences (India)
• Dr. Reddy's Laboratories (India)

These companies possess capabilities for complex chemical synthesis, strict quality standards, and scalable production.

Manufacturing considerations

• Synthetic complexity: Ripretinib's synthesis involves several steps with specific stereochemistry considerations, limiting the number of qualified manufacturers.
• Quality standards: APIs must meet stringent Quality, Dosage, and Regulatory requirements, including cGMP compliance.
• Supply chain: Most API sources are located in China and India, with some in Europe. Supply chain risks include geopolitical factors and pandemic disruptions.

Regulatory status and sourcing transparency

• Novartis produces ripretinib internally, with limited external API sourcing data publicly reported.
• Chinese and Indian manufacturers supply bulk APIs to various generic and branded drug producers under strict quality agreements.
• Regulatory documentation: API suppliers must provide Certificates of Analysis (CoA), stability data, and manufacturing process details for regulatory filings.

Market dynamics influencing API sourcing

• Increasing demand for ripretinib due to approved indications drives supply chain expansion.
• API price fluctuations depend on raw material availability, manufacturing capacity, and regulatory compliance.
• Supply security relies on diversified sourcing and partnerships.

Summary

Primary sources of bulk ripretinib API include internal production by Novartis, alongside contract manufacturers in China and India such as WuXi STA, Zhejiang Hisun, Jubilant, and Dr. Reddy’s. These suppliers provide complex synthesis capabilities, supported by regulatory compliance and supply chain management. The API's synthesis complexity and quality requirements limit the number of qualified sources, creating a concentrated supplier landscape.

Key Takeaways

• Novartis predominantly produces ripretinib API internally.
• China and India are leading external API suppliers.
• Contract manufacturing organizations like WuXi STA support clinical and commercial supply.
• Synthesis complexity constrains the number of capable API producers.
• Supply chain risks are mitigated through diversified sourcing strategies.

FAQs

1. Can other manufacturers produce ripretinib API?
Yes, contract manufacturers such as WuXi STA, Zhejiang Hisun, and Jubilant Life Sciences have the capability to produce ripretinib API under cGMP standards.

2. Are there approved alternatives for API sourcing?
Currently, most ripretinib API is sourced through established producers within China, India, and Novartis’s own manufacturing units. Alternative sources are limited due to synthesis complexity and regulatory requirements.

3. How does synthesis complexity affect API sourcing?
The complex multi-step synthesis with stereochemical precision limits qualified manufacturers, reducing the number of potential API suppliers.

4. What role do regulatory agencies play in API sourcing?
Regulatory agencies require detailed documentation—Certificates of Analysis, stability data, and manufacturing process descriptions—that suppliers must provide for approval and compliance.

5. How might geopolitical factors influence API availability?
Trade restrictions, tariffs, and export controls in China and India can impact API supply stability, prompting companies to diversify sources.

---

References

[1] U.S. Food and Drug Administration. (2021). FDA approvals of kinase inhibitors.
[2] PharmTech.com. (2022). API manufacturing landscape in China and India.
[3] European Medicines Agency. (2022). Guidelines on API quality and manufacturing standards.